The weight loss market, led by Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, is evolving with potential new approvals on the horizon. Wegovy, containing semaglutide, mimics GLP-1 hormones to regulate insulin and satiety, while Novo Nordisk’s CagriSema, a dual agonist, targets both GLP-1 and amylin for enhanced effectiveness. This dual approach parallels Eli Lilly’s Zepbound, a dual GLP-1/GIP agonist. The competitive landscape continues to shift as these companies advance their innovative treatments.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
